We rank companies based on fund manager, research analyst and news sentiment
ICAD stock icon

Icad Inc


About: icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Employees: 69

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

4% less funds holding

Funds holding: 50 [Q3] → 48 (-2) [Q4]

4.91% less ownership

Funds ownership: 28.25% [Q3] → 23.34% (-4.91%) [Q4]

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

28% less capital invested

Capital invested by funds: $15.2M [Q3] → $10.9M (-$4.29M) [Q4]

45% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 20

98% less call options, than puts

Call options by funds: $1.06K | Put options by funds: $65.7K

Research analyst outlook

We haven’t received any recent analyst ratings for ICAD.

Financial journalist opinion

Based on 4 articles about ICAD published over the past 30 days